HALOZYME THERAPEUTICS, INC. (HALO) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.79%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 3.79% | Share-based compensation / revenue. Period ending 2026-06-30. $63.07M ÷ $1.66B × 100 ≈ 3.79% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 1.66B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 63.07M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 597.20M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.66B | $63.07M | $597.20M | (m) | (m) | 3.79% | (m) | (m) |
| 2026-03-31 | (m) | $1.51B | $57.53M | $511.99M | (m) | (m) | 3.81% | (m) | (m) |
| 2025-12-31 | (m) | $1.40B | $51.56M | $469.01M | (m) | (m) | 3.69% | (m) | (m) |
| 2025-09-30 | $70.03M | $1.24B | $46.46M | $737.40M | (m) | 5.63% | 3.74% | (m) | (m) |
| 2025-06-30 | $71.24M | $1.18B | $46.87M | $682.67M | (m) | 6.04% | 3.98% | (m) | (m) |
| 2025-03-31 | $74.74M | $1.08B | $44.18M | $597.47M | (m) | 6.89% | 4.07% | (m) | (m) |
| 2024-12-31 | $79.05M | $1.02B | $43.38M | $551.48M | (m) | 7.79% | 4.27% | (m) | (m) |
| 2024-09-30 | $79.94M | $947.36M | $41.59M | $477.01M | (m) | 8.44% | 4.39% | (m) | (m) |
| 2024-06-30 | $78.81M | $873.30M | $38.38M | $402.09M | (m) | 9.02% | 4.39% | (m) | (m) |
| 2024-03-31 | $77.50M | $862.99M | $38.53M | $379.31M | $18.73M | 8.98% | 4.46% | 20.26× | Reported |
| 2023-12-31 | $76.36M | $829.25M | $36.62M | $337.57M | $18.76M | 9.21% | 4.42% | 17.99× | Reported |
| 2023-09-30 | $77.59M | $780.71M | $34.18M | $311.05M | $18.11M | 9.94% | 4.38% | 17.17× | Reported |
| 2023-06-30 | $76.98M | $773.65M | $31.61M | $306.06M | $21.12M | 9.95% | 4.09% | 14.49× | Reported |
| 2023-03-31 | $72.73M | $704.98M | $27.62M | $245.66M | $19.73M | 10.32% | 3.92% | 12.45× | Reported |
| 2022-12-31 | $66.61M | $660.12M | $24.40M | $267.53M | $16.95M | 10.09% | 3.70% | 15.79× | Reported |
| 2022-09-30 | $54.15M | $580.62M | $22.30M | $249.56M | $14.43M | 9.33% | 3.84% | 17.29× | Reported |
| 2022-06-30 | $45.93M | $487.48M | $20.90M | $241.85M | $8.67M | 9.42% | 4.29% | 27.89× | Reported |
| 2022-03-31 | $38.52M | $471.57M | $20.64M | $300.84M | $7.32M | 8.17% | 4.38% | 41.10× | Reported |
| 2021-12-31 | $35.67M | $443.31M | $20.82M | $275.90M | $7.53M | 8.05% | 4.70% | 36.66× | Reported |
| 2021-09-30 | $32.94M | $463.01M | $19.89M | $296.99M | $10.51M | 7.12% | 4.30% | 28.27× | Reported |
| 2021-06-30 | $32.20M | $412.50M | $18.71M | $261.70M | $13.74M | 7.81% | 4.54% | 19.04× | Reported |
| 2021-03-31 | $33.09M | $331.26M | $17.60M | $198.21M | $17.00M | 9.99% | 5.31% | 11.66× | Reported |
| 2020-12-31 | $34.24M | $267.59M | $17.20M | $144.25M | $20.38M | 12.79% | 6.43% | 7.08× | Reported |
| 2020-09-30 | $71.97M | $199.56M | $20.24M | $34.57M | $19.07M | 36.06% | 10.14% | 1.81× | Reported |
| 2020-06-30 | $94.67M | $180.47M | $24.26M | $-30.27M | $16.16M | 52.46% | 13.44% | -1.87× | Reported |
| 2020-03-31 | $119.63M | $164.40M | $29.83M | $-73.80M | $13.77M | 72.77% | 18.15% | -5.36× | Reported |
| 2019-12-31 | $140.80M | $195.99M | $34.78M | $-67.61M | $11.63M | 71.84% | 17.74% | -5.81× | Reported |
| 2019-09-30 | $132.34M | $202.56M | $36.56M | $-35.62M | $11.65M | 65.34% | 18.05% | -3.06× | Reported |
| 2019-06-30 | $137.43M | $181.88M | $37.19M | $-36.56M | $13.86M | 75.56% | 20.45% | -2.64× | Reported |
| 2019-03-31 | $143.60M | $177.94M | $36.83M | $-42.65M | $16.02M | 80.70% | 20.70% | -2.66× | Reported |
| 2018-12-31 | $150.25M | $151.86M | $35.70M | $-69.33M | $18.04M | 98.94% | 23.51% | -3.84× | Reported |
| 2018-09-30 | $154.98M | $281.19M | $34.09M | $56.67M | $19.74M | 55.11% | 12.12% | 2.87× | Reported |
| 2018-06-30 | $153.43M | $319.37M | $32.98M | $90.22M | $21.00M | 48.04% | 10.33% | 4.30× | Reported |
| 2018-03-31 | $151.68M | $317.92M | $31.69M | $84.82M | $21.77M | 47.71% | 9.97% | 3.90× | Reported |
| 2017-12-31 | $150.64M | $316.61M | $30.67M | $81.00M | $21.98M | 47.58% | 9.69% | 3.68× | Reported |
| 2017-09-30 | $150.62M | $166.05M | $30.01M | $-67.50M | $22.13M | 90.70% | 18.07% | -3.05× | Reported |
| 2017-06-30 | $150.49M | $134.17M | $28.90M | $-98.32M | $21.84M | 112.16% | 21.54% | -4.50× | Reported |
| 2017-03-31 | $147.68M | $133.76M | $27.08M | $-94.57M | $21.55M | 110.40% | 20.25% | -4.39× | Reported |
| 2016-12-31 | $150.84M | $146.69M | $25.59M | $-83.21M | $19.98M | 102.83% | 17.44% | -4.17× | Reported |
| 2016-09-30 | $137.24M | $159.91M | $24.09M | $-55.17M | $15.68M | 85.82% | 15.07% | -3.52× | Reported |
| 2016-06-30 | $130.99M | $148.84M | $22.99M | $-55.66M | $11.73M | 88.00% | 15.45% | -4.75× | Reported |
| 2016-03-31 | $116.65M | $158.89M | $22.52M | $-29.71M | $7.78M | 73.42% | 14.18% | -3.82× | Reported |
| 2015-12-31 | $93.24M | $135.06M | $20.84M | $-27.45M | $5.20M | 69.03% | 15.43% | -5.28× | Reported |
| 2015-09-30 | $85.22M | $113.21M | $19.80M | $-36.77M | $5.28M | 75.28% | 17.49% | -6.97× | Reported |
| 2015-06-30 | $77.51M | $107.03M | $18.42M | $-32.56M | $5.35M | 72.42% | 17.21% | -6.08× | Reported |
| 2015-03-31 | $74.97M | $82.03M | $16.11M | $-51.73M | $5.50M | 91.38% | 19.64% | -9.40× | Reported |
| 2014-12-31 | $79.70M | $75.33M | $15.27M | $-63.04M | $5.58M | 105.79% | 20.28% | -11.29× | Reported |
| 2014-09-30 | $80.89M | $57.46M | $13.46M | $-80.51M | $4.93M | 140.79% | 23.43% | -16.33× | Reported |
| 2014-06-30 | $86.68M | $58.86M | $11.59M | $-79.98M | $4.41M | 147.25% | 19.69% | -18.16× | Reported |
| 2014-03-31 | $96.02M | $54.93M | $10.44M | $-87.16M | $3.80M | 174.80% | 19.00% | -22.92× | Reported |
| 2013-12-31 | $96.64M | $54.80M | $9.54M | $-80.43M | $3.27M | 176.35% | 17.41% | -24.57× | Reported |
| 2013-09-30 | $94.28M | $64.09M | $9.13M | $-63.52M | (m) | 147.10% | 14.24% | (m) | (m) |
| 2013-06-30 | $88.10M | $53.42M | $8.74M | $-65.05M | (m) | 164.93% | 16.37% | (m) | (m) |
| 2013-03-31 | $76.19M | $46.72M | $8.59M | $-56.98M | (m) | 163.08% | 18.39% | (m) | (m) |
| 2012-12-31 | $70.04M | $42.33M | $8.35M | $-53.63M | (m) | 165.49% | 19.72% | (m) | (m) |
| 2012-09-30 | $66.39M | $22.94M | $8.02M | $-67.65M | (m) | 289.38% | 34.94% | (m) | (m) |
| 2012-06-30 | $60.40M | $40.55M | $7.85M | $-42.46M | (m) | 148.96% | 19.36% | (m) | (m) |
| 2012-03-31 | $59.67M | $55.98M | $6.79M | $-25.32M | (m) | 106.58% | 12.14% | (m) | (m) |
| 2011-12-31 | $57.56M | $56.09M | $5.57M | $-19.84M | (m) | 102.63% | 9.93% | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $51.77M | $13.62M | $4.87M | $-54.26M | (m) | 380.01% | 35.72% | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $56.61M | $13.67M | $4.53M | $-58.46M | (m) | 414.11% | 33.11% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |